Skip to main content

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Trial Status: Administratively Complete

This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Currently enrolling melanoma patients in combination with nivolumab, only.

Inclusion Criteria

  • Inclusion Criteria: Participants must meet all of the following inclusion criteria to be eligible to enroll in the Part C of this study. 1. Should have unresectable advanced, recurrent or metastatic melanoma and must have objective and measurable melanoma by RECIST 1.1 after disease progression on a prior anti-PD-1 or anti-PD-L1 therapy. 2. ECOG performance status of ≤ 2. 3. Life expectancy of ≥ 3 months. 4. Adequate hepatic function: - Total bilirubin < 1.5 times the ULN (except participants with Gilbert's syndrome [hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3 times ULN), - AST and ALT ≤ 2.5 times ULN (except participants with known liver involvement of their advanced solid malignancy who must have an AST and ALT ≤ 5.0 times ULN). 5. Adequate renal function: - Estimated creatinine clearance of ≥ 60 mL/min, calculated using the formula of Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if female. 6. Adequate hematopoietic function: - Total WBC count ≥ 1500/mm³, ANC ≥ 1000/mm³, Hb ≥ 10.0 g/dL, platelet count ≥ 100,000/mm³ Exclusion Criteria: Participants meeting any of the following exclusion criteria are not eligible to enroll in this study. 1. ≤ 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids for disease related symptoms < 7 days prior to C1D1, unless physiologic doses of steroids are used. 2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic toxicities, ≤ Gr 2 or to their baseline for hematologic toxicities) from toxicities related to their previous treatment except for alopecia. 3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without active brain or leptomeningeal metastases after prior treatment with local therapies are eligible provided that the treatment had been done ≥ 2 weeks prior to enrollment. 4. Active infection with completion of therapeutic antibiotics, antivirals, or antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or antifungals are permitted. 5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea that could interfere with the absorption of KPT-9274. 6. Active peptic ulcer disease or other active gastrointestinal bleeds. 7. Requiring treatment with corticosteroids at doses higher than substitute therapy (> 10 mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be likely to re-occur by the treating physician when administered nivolumab.


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Contact: Ignacio Baselga Carretero
Phone: 310-206-3928


University of Colorado Hospital
Contact: Tara Ames Wells
Phone: 720-848-0755

District of Columbia

MedStar Georgetown University Hospital
Status: ACTIVE


Mayo Clinic in Rochester
Contact: Rebecca Thomason

New York

New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Contact: Karen Martirosyan
Phone: 212-263-4434


Vanderbilt University / Ingram Cancer Center


M D Anderson Cancer Center
Contact: Aung Naing
Phone: 713-563-1930

This is a first-in-human, multi-center, open-label clinical study with separate Dose

Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of

KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies

(including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic

options considered useful by the investigator have been exhausted.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Karyopharm Therapeutics Inc

  • Primary ID KCP-9274-901
  • Secondary IDs NCI-2016-00611, s16-00464
  • ID NCT02702492